India's largest IT company, Tata Consultancy Services (TCS), announced on Monday the launch of its proprietary agent AI platform named TCS ADD™ AgentHub. This platform is designed for the scalable use of AI agents in the drug development process.
According to a report presented by TCS, this platform is capable of transforming clinical trial and pharmacovigilance services while ensuring compliance with regulatory and auditing requirements. TCS noted that pharmaceutical companies operate in strictly regulated environments and face challenges related to trust, governance, and scalability when implementing AI across all functions.
Difficulties in the R&D value chain are exacerbated by growing data volumes, system fragmentation, and increasing regulatory expectations in clinical development and pharmacovigilance. In response to these challenges, TCS stated that its platform will provide 'a structured framework to mitigate these issues,' allowing AI agents to function with clearly defined roles, oversight, and built-in verifiability.
The company emphasized that pharmaceutical firms can create and deploy customized AI agent centers within clinical workflows with minimal integration and implementation effort, while maintaining regulatory compliance. The platform ensures fast and simplified integration, accelerating adoption while adhering to regulatory norms.
Built on TCS's agent AI architecture, TCS ADD™ AgentHub also allows pharma companies to adopt a 'Human + AI' model, integrating AI agents into corporate workflows while preserving human control and accountability for decision-making and management. TCS stated that the platform delivers measurable operational advantages in drug development and drug safety functions.
According to TCS, solutions based on this platform have demonstrated the following results: up to 40 percent improvement in clinical data management efficiency; up to 30 percent reduction in clinical trial creation efforts through metadata-based automation; up to 30 percent cost savings on end-to-end safety case processing; and up to 50 percent reduction in quality control efforts using AI-based safety agents.
Debashis Ghosh, President of TCS Lifesciences and Healthcare, noted that the company's strategy is aimed at transitioning to autonomous corporate functions, where AI agent-powered workforce works side-by-side with humans to drive innovation in drug development and enhance patient safety. The company also expressed its ambition to become the world's largest AI-driven technology company, reflected in its comprehensive 'AI-first' culture, exemplified by TCS ADD™ AgentHub. TCS asserts that by leveraging the patented cognitive intelligence of the TCS ADD™ suite, it provides its clients with tangible, predictable, and secure digital ecosystems.